Premium
Vortioxetine for the treatment of major depression in adults
Author(s) -
Chaplin Steve
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1445
Subject(s) - vortioxetine , medicine , antidepressant , depression (economics) , nice , adverse effect , psychiatry , clinical trial , anxiety , computer science , economics , macroeconomics , programming language
Vortioxetine (Brintellix) is a new antidepressant recently recommended by NICE as third‐line therapy for the treatment of major depressive episodes in adults. This article describes the drug's properties, clinical trial evidence for its efficacy and its adverse effects.